In addition, a recent 3rd-generation EGFR-TKI, osimertinib, had a statistically significant and clinically meaningful improvement in disease-free survival in patients with common sensitive EGFR-mutated NSCLC after complete tumor resection and adjuvant chemotherapy [10, 24]. The gene discussed is EGFR; the disease is neoplasm.